Literature DB >> 8612471

Tiaprofenic acid. A reappraisal of its pharmacological properties and use in the management of rheumatic diseases.

G L Plosker1, A J Wagstaff.   

Abstract

Tiaprofenic acid is a nonsteroidal anti-inflammatory drug (NSAID) used in the treatment of patients with rheumatic diseases and other clinical conditions of pain and inflammation. Like other propionic acid derivatives, tiaprofenic acid is effective and generally well tolerated. Comparative studies in patients with rheumatoid arthritis or osteoarthritis receiving tiaprofenic acid 600 mg/day demonstrated improvements in pain intensity, duration of morning stiffness, articular index and other clinical variables which were similar to those achieved with alternative NSAIDs. Tolerability was also comparable between tiaprofenic acid and other NSAIDs in most trials; the most frequently reported adverse events involved the gastrointestinal tract. Some studies showed a trend towards fewer patient withdrawals because of adverse events with tiaprofenic acid than with NSAIDs such as indomethacin. Current evidence suggests that nonbacterial cystitis is more likely to be associated with tiaprofenic acid than with other NSAIDs. This reaction should, however, be considered in the perspective of its infrequent occurrence and its typical reversibility, and against the wider background of the established usage of tiaprofenic acid and its overall tolerability profile which is similar to that of other NSAIDs. Unlike indomethacin, tiaprofenic acid was not associated with increased cartilage degradation in a recently completed large clinical trial known as LINK, which evaluated the effects of long term administration in patients with osteoarthritis of the knee. Thus, tiaprofenic acid is an established option among the range of NSAIDs used in the treatment of patients with rheumatic diseases, with efficacy and tolerability profiles that are relatively well characterised. The availability of a sustained release dosage form of tiaprofenic acid, which has a similar efficacy and tolerability profile to the standard formulation, provides a convenient once daily dosage regimen.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8612471     DOI: 10.2165/00003495-199550060-00010

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  99 in total

1.  Hepatotoxicity to several nonsteroidal anti-inflammatory drugs with diclofenac induced histological changes.

Authors:  A O Adebajo; C J Eastmond
Journal:  Clin Rheumatol       Date:  1992-03       Impact factor: 2.980

2.  Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs.

Authors:  L A García Rodríguez; H Jick
Journal:  Lancet       Date:  1994-03-26       Impact factor: 79.321

3.  Clinical experiences with the intramuscular injection of tiaprofenic acid in rheumatic diseases, with particular emphasis on time of onset and duration of the analgesic effect.

Authors:  G Katona; R Burgos-Vargas
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  Effects of tiaprofenic acid on the concentration and metabolism of proteoglycans in normal and degenerating canine articular cartilage.

Authors:  K D Brandt; M E Albrecht; L A Kalasinski
Journal:  J Clin Pharmacol       Date:  1990-09       Impact factor: 3.126

5.  Spontaneous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs. A report from the Spanish System of Pharmacovigilance, including an early analysis of topical and enteric-coated formulations.

Authors:  A Figueras; D Capellà; J M Castel; J R Laorte
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

6.  Tiaprofenic acid as a cause of non-bacterial cystitis.

Authors:  G F O'Neill
Journal:  Med J Aust       Date:  1994-02-07       Impact factor: 7.738

7.  In vitro effects of tiaprofenic acid, sodium salicylate and hydrocortisone on the proteoglycan metabolism of human osteoarthritic cartilage.

Authors:  J P Pelletier; J M Cloutier; J Martel-Pelletier
Journal:  J Rheumatol       Date:  1989-05       Impact factor: 4.666

8.  Reduction of urinary excretion of PGE2 and 6 keto PGF1 alpha by tiaprofenic acid.

Authors:  C J Lote; A J McVicar; A Thewles
Journal:  Br J Pharmacol       Date:  1985-05       Impact factor: 8.739

9.  Effects of tiaprofenic acid and acetylsalicylic acid on human articular chondrocytes in 3-dimensional culture.

Authors:  C T Bassleer; Y E Henrotin; J L Reginster; P P Franchimont
Journal:  J Rheumatol       Date:  1992-09       Impact factor: 4.666

10.  Comparison of gastrointestinal blood loss in healthy male volunteers during repeated administration of standard and sustained action tiaprofenic acid and sustained release indomethacin.

Authors:  S J Warrington; J Dana-Haeri; M A Horton; E J Thornton
Journal:  Drugs       Date:  1988       Impact factor: 9.546

View more
  1 in total

Review 1.  Clinical pharmacokinetics of tiaprofenic acid and its enantiomers.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.